Johnson & Johnson Q2 earnings to spotlight new drugs and pipeline

Johnson & Johnson is set to report its second-quarter earnings, with investors focused on its new products and drug pipeline rather than just its defensive rotation appeal. The healthcare giant aims to prove its growth credentials go beyond being a safe-haven pick in volatile markets. New product launches and pipeline progress will be the key metrics under scrutiny.